Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) With or Without Durvalumab (MEDI4736) in Oligometastatic Recurrent Hormone Sensitive Prostate Cancer Patients

NCT03795207 is registered in ClinicalTrials.gov with Institut Cancerologie de l'Ouest as lead sponsor.

NCT NCT03795207
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03795207 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) With or Without Durvalumab (MEDI4736) in Oligometastatic Recurrent Hormone Sensitive Prostate Cancer Patients
Lead sponsor
Institut Cancerologie de l'Ouest
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 21, 2019
Completion date
December 27, 2027
Enrollment
96 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

bone metastases, node; prostate, prostate cancer patients